One-Year Efficacy of OMNI Canaloplasty With and Without Additional Hydrus Microstent During Cataract Surgery

After 1 year, OMNI canaloplasty, with or without a Hydrus Microstent, achieved comparable surgical outcomes, reductions in IOP, and medication reduction.

This study compares the 1-year effectiveness of performing a canaloplasty during concurrent cataract surgery (CS) with or without a microstent in patients with glaucoma.

A retrospective analysis was performed on 66 eyes: 33 received OMNI canaloplasty, and 33 received OMNI canaloplasty with an additional Hydrus Microstent during CS. The mean number of ocular hypotensive medications and intraocular pressure (IOP) were assessed after 1 year. The primary outcome was surgical success, defined as attaining the target IOP without additional medications or procedures. Eyes were matched (1:1) based on demographics and disease characteristics. Statistical analysis included paired t tests and regression modeling.

Mean IOP at 1 year was reduced by 18.0% in the canaloplasty alone group and by 12.8% in the canaloplasty with microstent group ( P =0.445). Mean medications at 1 year were reduced by 47.8% in the canaloplasty alone group and by 60.0% in the canaloplasty with microstent group ( P =0.554). Surgical success at 1 year was 75.8% for canaloplasty alone and 87.9% for canaloplasty with microstent ( P =0.339). The total adverse event rate was 9.09% (n=6).

Combining canaloplasty with a microstent did not yield statistically significant improvements in surgical success, IOP reduction, medication use, or safety outcomes at 1 year compared with standalone canaloplasty. This suggests that, for patients undergoing CS with concurrent canaloplasty, the addition of a microstent may not confer substantial long-term clinical benefit. Small cohort size and differences in population between groups may also affect this outcome.